Metabolism of ticagrelor in patients with acute coronary syndromes

Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Adamski, Piotr, Buszko, Katarzyna, Sikora, Joanna, Niezgoda, Piotr, Barańska, Malwina, Ostrowska, Małgorzata, Paciorek, Przemysław, Navarese, Eliano P., Gorog, Diana A., Kubica, Jacek
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6078957/
https://ncbi.nlm.nih.gov/pubmed/30082687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-29619-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak